Abstract
Bleeding continues to be a major adverse drug event associated with warfarin anticoagulation. The cornerstone of warfarin-related bleeding management involves repletion of affected plasma coagulation factor levels. Prothrombin complex concentrate (human) is a 4-factor prothrombin complex concentrate that contains vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S. It recently received Food and Drug Administration approval for warfarin reversal for patients with major bleeding or requiring urgent surgery or other invasive procedures. Its role in reversing target-specific oral anticoagulants appears to be limited to the Factor Xa inhibitors as an emergent intervention.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Johnson JA. Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation. 2012;125:1964–6.
Jacobson A. Is there a role for warfarin anymore? Hematology. 2012;2012:542–6.
Chesebro JH, Wiebers DO, Holland AE, et al. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409–16.
Schulman S, Beyth RJ, Kearon C, Levine MN. American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(suppl 6):257S–98S.
Budnitz DS, Lovegrove MC, Shehab N. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106.
Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med. 2011;12(4):386–92.
Navgren M, Forsblad J, Wieloch M. Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital. J Thromb Thrombolysis. 2013;Epub ahead of print.
Hirsch J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8S–21S.
Gulati G, Hevelow M, George M, et al. International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. Arch Pathol Lab Med. 2011;135:490–4.
Stirling Y. Warfarin-induced changes in procoagulant and anticoagulant proteins. Blood Coagul Fibrinolysis. 1995;6(5):361–73.
Nutescu EA, Dager WE, Kalus JS, et al. Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. Am J Health Syst Pharm. 2013;70:1914–29.
CSL Behring. KcentraTM (prothrombin complex concentrate [Human]): prescribing information [online] 2014 01/28/2014 Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM350239.pdf.
Kerebel D, Joly LM, Honnart D, et al. A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal. Critical Care. 2013;17R4.
Vang ML, Hvas AM, Ravn HB. Urgent reversal of vitamin K antagonist therapy. Acta Anaesthesiol Scand. 2011;55:507–16.
Kaatz S, Crowther M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis. 2013;36(2):195–202.
Nitzki-George D, Wozniak I, Caprini JA. Current state of knowledge of oral anticoagulation reversal using procoagulant factors. Ann Pharmacother. 2013;47:841–55.
•• Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin k antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43. This is the only randomized, controlled trial comparing a 4 factor prothrombin complex concentration to plasma. Warfarin reversal was achieved significantly faster in 4 factor prothrombin complex concentrate group compared to plasma although there was no difference at 24 hours.
Hollbrook A, Shulman S, Witt DW, et al. Evidence-based management of anticoagulation therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):e152S–84S.
Schick KS, Fertmann JM, Jauch KW, et al. Prothrombin complex concentrate in surgical patients: retrospecitve evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care. 2009;13:R191.
Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex ® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622–31.
Pinner NA, Hurdle AC, Oliphant C, et al. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII. World Neurosurg. 2010;74(6):631–5.
CSL Behring news release. Kcentra®, from CSL Behring, Receives FDA Approval for Use in Warfarin Reversal in Patients Undergoing Surgery. December 13, 2013. http://www.cslbehring.com/newsroom/Kcentra-Earns-FDA-Approval-for-Use-in-Patients-Undergoing-Surgery?tabSelections=1255923338766¤tPage=1. Accessed 28 Jan 2014.
• Kalus JS. Pharmacologic interventions for reversing the effects of oral anticoagulants. Am J Health Syst Pharm. 2013;70(Suppl 1):S12–21. This article provides guidance for the reversal of all oral anticoagulants with the available treatments based on current literature and expert opinion.
Tran HA, Chunilal SD, Harper PL, et al. An update of consensus guidelines for warfarin reversal. Med J Aust. 2013;198(4):198–9.
Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol. 2011;154:311–24.
•• Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–79. This study reviewed the impact of 4 factor prothrombin complex in reversing laboratory parameters of anticoagulation in normal volunteers treated with dabigatran and rivaroxaban.
Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87:S141–5.
Kaatz S, Crowther M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis. 2013;36(2):195–202.
Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010;8:149–54.
Riess HB, Meier-Hellmann A, Motsch J, et al. Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation. Thromb Res. 2007;121:9–16.
Song MM, Warne CP, Crowther MA. Prothrombin complex concentrate (PP, Octaplex®) in patients requiring immediate reversal of vitamin K antagonist anticoagulation. Thromb Res. 2012;129:526–9.
Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137–43.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reardon, D.P., Connors, J.M. Prothrombin Complex Concentrate (4PCC): A Review of its Use in Reversal of Vitamin K Antagonists. Curr Emerg Hosp Med Rep 3, 50–54 (2015). https://doi.org/10.1007/s40138-014-0058-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40138-014-0058-2